Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
New vaccine in bid to move away from needles and syringes to skin delivery procedures

New vaccine in bid to move away from needles and syringes to skin delivery procedures

Drug delivery technologies that improve access and overall efficacy are becoming an essential part of the entire drug development process. [More]
Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

Semi-soft vaginal suppository provides drug-delivery vehicle to prevent spread of HIV

A unique method for delivering compounds that could positively impact the global battle against HIV and AIDS may be possible, thanks to researchers in Penn State's College of Agricultural Sciences. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

Report on Co-development Terms & Agreements in Pharma, Biotech and Diagnostics

The Co-development Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. [More]
TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

TWi Pharmaceuticals obtains final approval from FDA for megestrol acetate 125mg/ml oral suspension

TWi Pharmaceuticals, Inc. today announced that it has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for megestrol acetate 125mg/ml oral suspension, the generic equivalent to Par Pharmaceutical's Megace ES. [More]
BD announces winners of 2014 "Innovations in Care" awards

BD announces winners of 2014 "Innovations in Care" awards

BD (Becton, Dickinson and Company), a leading global medical technology company – together with Direct Relief and the National Association of Community Health Centers – has announced the winners of the 2014 "Innovations in Care" awards to seven community health centers as part of the BD Helping Build Healthy CommunitiesSM initiative. [More]
iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

First peer-reviewed comprehensive expert guidance on the use of neurostimulation for pain

Reflecting groundbreaking international consensus regarding a group of rapidly evolving medical interventions for chronic pain, the International Neuromodulation Society announced it will soon publish the first peer-reviewed comprehensive expert guidance on the appropriate use of neurostimulation for pain. [More]
Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi, MannKind sign licensing agreement to develop and commercialize Afrezza Inhalation Powder

Sanofi and MannKind Corporation announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. [More]
New lifesaving product aims at reducing death toll from heroin abuse

New lifesaving product aims at reducing death toll from heroin abuse

A new, lifesaving product aimed at reducing the death toll from heroin abuse — developed by a professor at the University of Kentucky College of Pharmacy — is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration. [More]
New tool promises to reduce deaths caused by heroin overdose

New tool promises to reduce deaths caused by heroin overdose

A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration. [More]
Access Pharmaceuticals enters into exclusive license agreement with Norgine

Access Pharmaceuticals enters into exclusive license agreement with Norgine

ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with Norgine B.V., a leading independent European specialty pharmaceutical company, for the commercialization of MuGard in Europe. [More]
Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Rheumatoid arthritis is a condition that causes painful inflammation of several joints in the body. The joint capsule becomes swollen, and the disease can also destroy cartilage and bone as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world's population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease. [More]
BD Medical announces retail pharmacy launch of BD AutoShield Duo

BD Medical announces retail pharmacy launch of BD AutoShield Duo

BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the retail pharmacy launch of BD AutoShield Duo, the only pen needle with patented dual front and back-end shields that provides greater convenience and safety before and after injecting. [More]
BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences International, Inc. announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). [More]

Graphene droplets open up possibilities for use in drug delivery and disease detection

A chance discovery about the 'wonder material' graphene - already exciting scientists because of its potential uses in electronics, energy storage and energy generation - takes it a step closer to being used in medicine and human health. [More]
Researchers to track fate in body of materials used in breakthrough medicines

Researchers to track fate in body of materials used in breakthrough medicines

The University of Liverpool has been awarded -2 million to become a leading centre in the UK for tracking the fate in the body of materials used in breakthrough medicines. [More]
New information on limitations and potential for development of transcranial ultrasound therapy

New information on limitations and potential for development of transcranial ultrasound therapy

A recent study completed at the University of Eastern Finland provides new information on the limitations and potential new directions for the future development of transcranial ultrasound therapy. [More]
BD reports 5.1% increase in third fiscal quarter revenues

BD reports 5.1% increase in third fiscal quarter revenues

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014, representing an increase of 5.1 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis. [More]
Antioxidant biomaterial helps vascular grafts heal

Antioxidant biomaterial helps vascular grafts heal

When a foreign material like a medical device or surgical implant is put inside the human body, the body always responds. According to Northwestern University's Guillermo Ameer, most of the time, that response can be negative and affect the device's function. [More]